BDP

FDA Approves Immunotherapy for a Cancer that Affects Infants and Children

Gloved hand holding a vial

By Frank Blanchard, Staff Writer

The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.

Tags: 

BDP Is Unified at the ATRF

A man attaches a valve to a tank..

By Ken Michaels, Staff Writer

The Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory is, for the first time ever, in a single building at the Advanced Technology Research Facility (ATRF).

At Fort Detrick, BDP operations were spread out in about a dozen buildings, resulting in redundancies in maintaining various utilities (air handlers, clean steam, WFI, etc.) for multiple buildings rather than one.

Tags: 

Subscribe to BDP